284 related articles for article (PubMed ID: 1663044)
1. Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
RodrÃguez-Pena MS; Guijarro LG; Prieto JC
Eur J Pharmacol; 1991 Nov; 208(3):207-12. PubMed ID: 1663044
[TBL] [Abstract][Full Text] [Related]
2. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages.
Pozo D; Montilla ML; Guerrero JM; Calvo JR
Eur J Pharmacol; 1997 Mar; 321(3):379-86. PubMed ID: 9085051
[TBL] [Abstract][Full Text] [Related]
3. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.
Waelbroeck M; Robberecht P; Coy DH; Camus JC; De Neef P; Christophe J
Endocrinology; 1985 Jun; 116(6):2643-9. PubMed ID: 2859987
[TBL] [Abstract][Full Text] [Related]
4. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle.
Chakder S; Rattan S
J Pharmacol Exp Ther; 1993 Jul; 266(1):392-9. PubMed ID: 8392560
[TBL] [Abstract][Full Text] [Related]
5. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
Laburthe M; Couvineau A; Rouyer-Fessard C
Mol Pharmacol; 1986 Jan; 29(1):23-7. PubMed ID: 3003561
[TBL] [Abstract][Full Text] [Related]
6. Comparative structural requirements of thirty GRF analogs for interaction with GRF- and VIP receptors and coupling to adenylate cyclase in rat adenopituitary, liver and pancreas.
Robberecht P; Waelbroeck M; Coy D; De Neef P; Camus JC; Christophe J
Peptides; 1986; 7 Suppl 1():53-9. PubMed ID: 3018703
[TBL] [Abstract][Full Text] [Related]
7. [D-Phe4]peptide histidine-isoleucinamide ([D-Phe4]PHI), a highly selective vasoactive-intestinal-peptide (VIP) agonist, discriminates VIP-preferring from secretin-preferring receptors in rat pancreatic membranes.
Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
Eur J Biochem; 1987 Jun; 165(2):243-9. PubMed ID: 3036504
[TBL] [Abstract][Full Text] [Related]
8. Interaction of ovine pituitary adenylate cyclase-activating peptide (PACAP-38) with rat lung membranes.
Bitar KG; Coy DH
Peptides; 1993; 14(3):621-7. PubMed ID: 8392724
[TBL] [Abstract][Full Text] [Related]
9. Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes.
Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
Eur J Biochem; 1986 Aug; 159(1):45-9. PubMed ID: 3017717
[TBL] [Abstract][Full Text] [Related]
10. Heart receptors for VIP, PHI and secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and physiopathology.
Christophe J; Waelbroeck M; Chatelain P; Robberecht P
Peptides; 1984; 5(2):341-53. PubMed ID: 6089134
[TBL] [Abstract][Full Text] [Related]
11. Effects of vasoactive intestinal polypeptide antagonists on cholinergic neurotransmission in dog and cat trachea.
Xie ZQ; Hirose T; Hakoda H; Ito Y
Br J Pharmacol; 1991 Dec; 104(4):938-44. PubMed ID: 1667294
[TBL] [Abstract][Full Text] [Related]
12. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
[TBL] [Abstract][Full Text] [Related]
13. The effects of antagonists of vasoactive intestinal peptide on nonadrenergic noncholinergic inhibitory responses in feline airways.
Thompson DC; Altiere RJ; Diamond L
Peptides; 1988; 9(2):443-7. PubMed ID: 3131749
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of vasoactive intestinal peptide antagonists on blood flow in the rat thyroid.
Michalkiewicz M; Huffman LJ; Hedge GA
Peptides; 1991; 12(6):1181-6. PubMed ID: 1815206
[TBL] [Abstract][Full Text] [Related]
15. Adenylyl cyclase stimulation by VIP in rat seminal vesicle membranes.
Rodriguez-Pena MS; Guijarro LG; Prieto JC
Peptides; 1991; 12(4):821-4. PubMed ID: 1664946
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide and intraocular pressure: adenylate cyclase activation and binding sites for vasoactive intestinal peptide in membranes of ocular ciliary processes.
Mittag TW; Tormay A; Podos SM
J Pharmacol Exp Ther; 1987 Apr; 241(1):230-5. PubMed ID: 3033201
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
Juarranz MG; De Neef P; Robberecht P
Prostate; 1999 Sep; 41(1):1-6. PubMed ID: 10440869
[TBL] [Abstract][Full Text] [Related]
18. Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes.
Robberecht P; Coy DH; Waelbroeck M; Heiman ML; de Neef P; Camus JC; Christophe J
Endocrinology; 1985 Nov; 117(5):1759-64. PubMed ID: 2994998
[TBL] [Abstract][Full Text] [Related]
19. Properties of vasoactive-intestinal-peptide receptors and beta-adrenoceptors in the murine radiation leukemia-virus-induced lymphoma cell line BL/VL3.
Abello J; Damien C; De Neef P; Tastenoy M; Hooghe R; Robberecht P; Christophe J
Eur J Biochem; 1989 Aug; 183(2):263-7. PubMed ID: 2547606
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.
Wood CL; O'Dorisio MS; Vassalo LM; Malarkey WB; O'Dorisio TM
Regul Pept; 1985 Nov; 12(3):237-48. PubMed ID: 3001842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
